TRAF-1, -2, -3, -5, and -6 Are Induced in Atherosclerotic Plaques and Differentially Mediate Proinflammatory Functions of CD40L in Endothelial Cells
Overview
Authors
Affiliations
Objective: Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis. This study investigated the involvement of tumor necrosis factor receptor-associated factors (TRAFs) in CD40 signaling in endothelial cells (ECs) and their expression in atheromata and cells involved in atherogenesis.
Methods And Results: CD40L enhanced the basal expression of TRAF-1, -2, -3, and 6, but not TRAF-5 in ECs. TRAFs associated with CD40 on ligation by CD40L. Study of ECs from TRAF-1, -2, and -5-deficient mice demonstrated functional involvement of TRAFs in proinflammatory CD40 signaling. Whereas TRAF-1 deficiency enhanced CD40L-induced IL-6 and MCP-1 expression, TRAF-2 and TRAF-5 deficiency inhibited CD40L-inducible IL-6 but not MCP-1 expression. Gene silencing in human ECs further delineated functions of TRAFs in CD40 signaling. TRAF-3 silencing in ECs showed increased CD40L-induced IL-6, MCP-1, and IL-8 expression, whereas TRAF-6 silencing increased selectively CD40L-induced MCP-1 expression. Enhanced TRAF levels in atherosclerotic lesions further supports involvement of members of this family of signaling molecules in arterial disease.
Conclusions: These results implicate endothelial TRAF-1, -2, -3, -5, and -6 in CD40 signaling in atherogenesis, identifying these molecules as potential targets for selective therapeutic intervention.
Nitz K, Herrmann J, Lerman A, Lutgens E JACC Basic Transl Sci. 2024; 9(6):827-843.
PMID: 39070270 PMC: 11282889. DOI: 10.1016/j.jacbts.2023.12.007.
Influence of Race and High Laminar Shear Stress on TNFR1 Signaling in Endothelial Cells.
Aldokhayyil M, Gomez D, Cook M, Kavazis A, Roberts M, Geetha T Int J Mol Sci. 2023; 24(19).
PMID: 37834170 PMC: 10572906. DOI: 10.3390/ijms241914723.
Zhu M, Li X, Feng Y, Jia T, Li S, Gong L BMC Cancer. 2023; 23(1):845.
PMID: 37691121 PMC: 10494347. DOI: 10.1186/s12885-023-11367-3.
Vos S, Aaron R, Weng M, Daw J, Rodriguez-Rivera E, Subauste C Invest Ophthalmol Vis Sci. 2023; 64(7):17.
PMID: 37294707 PMC: 10259673. DOI: 10.1167/iovs.64.7.17.
Tiboldi A, Hunyadi-Gulyas E, Wohlrab P, Schmid J, Markstaller K, Klein K Antioxidants (Basel). 2022; 11(12).
PMID: 36552557 PMC: 9774699. DOI: 10.3390/antiox11122349.